Abbott Gmbh & Co Kg

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Volker Nimmrich

Wilfried Hornberger

Wilfried Lubisch

Andreas Kling

Helmut Mack

Chung-Ming Hsieh

Achim Moeller

Ulrich Ebert

Dietmar Seemann

Jijie Gu

Martin Schmidt

Reinhold Mueller

Enrico L Digiammarino

John E Harlan

Gerard B Fox

Ralf Loebbert

Feng Luo

Zhen Wu

Heinz Hillen

Stefan Barghorn

Carsten Krantz

Gerhard Gross

Andreas Draguhn

Claus Bruhl

Christine Grimm

Dietmar Seeman

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R, R, R, R, W, Y and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula I-A.a' and I-A.a&#x2033; in which m, E, R, R, R, R, R, Rand Rhave the meanings mentioned in the claims, n is 0, 1 or 2, the tautomers thereof and the pharmaceutically suitable salts thereof.

Carboxamide compounds and their use as calpain inhibitors

The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between A&#x3b2; globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject.

Method for the treatment of amyloidoses

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R, R, R, R, W, Y and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula I-A.a' and I-A.a&#x2033; in which m, E, R, R, R, R, R, Rand R* have the meanings mentioned in the claims, n is 0, 1 or 2, the tautomers thereof and the pharmaceutically suitable salts thereof.

Growing community of inventors

Ludwigshafen, Germany

Volker Nimmrich